-
-
7 . Periodical
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
- 저자
- by Nachman, Sharon; Alvero, Carmelita; Teppler, Hedy; Homony, Brenda; Rodgers, Anthony J, et al.
- 소스
- The Lancet HIV; December 2018, Vol. 5 Issue: 12 pe715-e722, 8p